




Revista Colombiana de REUMATOLOGÍA

www.elsevier.es/rcreuma



Original Investigation

Integrative analysis of datasets of proteins in Sjögren's syndrome patients



Luz Elena Triana Vidal^{a,*}, Nicolás Gutiérrez^b, Camilo Cardona^a,
Jorge Brayam Núñez Torres^a, Mónica Yulieth Agudelo Ocampo^a

^a Medicine Program, Research Group in Epidemiology and Services (Griepis), Faculty of Health Sciences, Universidad Libre, Cali, Colombia

^b Biology Program, Department of Natural Sciences and Mathematics, Biphotonics Research Group, Faculty of Engineering and Sciences, Pontificia Universidad Javeriana, Cali, Colombia

ARTICLE INFO

Article history:

Received 29 June 2021

Accepted 20 December 2021

Available online 22 February 2022

Keywords:

Sjögren's syndrome

Protein

Biomarker

Systematic comparison

ABSTRACT

This study aims to compare reported proteins expressed in controls and patients with SS in tear, saliva and serum from proteins identified in papers published between 2000 and 2020, to obtain a systematic comparison of proteins expressed in SS patients to find proteins that can be used as biomarkers in SS. Differentially expressed proteins from Sjögren's patients identified in the studies were classified by body fluid (saliva, serum, tear and saliva from healthy patients). Protein pairing was carried out in RStudio, using the previously created data framework, PANTHER and REACTOME 7.0. were used to explore the type of proteins associated with SS and enriched metabolic pathways. Five differentially expressed proteins were found in saliva, tear, and serum. Finally, this study suggests antithrombin III and E-cadherin. as biomarkers in SS, because these proteins are differentially expressed in plasma, blood, and tear, and that neutrophil degranulation pathway as a target for SS.

© 2022 Asociación Colombiana de Reumatología. Published by Elsevier España, S.L.U. All rights reserved.

Análisis integrativo de proteínas reportadas con expresión diferencial en pacientes con síndrome de Sjögren

RESUMEN

Este estudio tiene como objetivo comparar las proteínas reportadas como diferencialmente expresadas en pacientes con síndrome de Sjögren (SS), en lágrima, saliva y suero, versus controles, a partir de proteínas identificadas en artículos publicados entre 2000 y 2020, a fin de encontrar una comparación sistemática de la proteína expresada en pacientes con SS y poder hallar proteínas que se puedan utilizar como biomarcadores en SS. Las proteínas expresadas diferencialmente de los pacientes de Sjögren identificadas en los estudios se clasificaron por fluido corporal (saliva, suero, lágrimas y saliva de pacientes sanos). El

Palabras clave:

Síndrome de Sjögren

Proteína

Biomarcador

Comparación sistemática.

* Corresponding author.

E-mail address: luz.trianav@unilibre.edu.co (L.E. Triana Vidal).

<https://doi.org/10.1016/j.rcreu.2021.12.002>

0121-8123/© 2022 Asociación Colombiana de Reumatología. Published by Elsevier España, S.L.U. All rights reserved.

emparejamiento de proteínas se realizó en RStudio, utilizando el marco de datos previamente creado, y se utilizó Panther y Reactome 7.0. para explorar el tipo de proteínas asociadas con SS y las vías metabólicas enriquecidas. Se encontraron 5 proteínas expresadas diferencialmente en saliva, lágrimas y suero. Este estudio muestra que la antitrombina III y la E-cadherina son biomarcadores en SS, como también que la vía de desgranulación de neutrófilos es la diana para SS.

© 2022 Asociación Colombiana de Reumatología. Publicado por Elsevier España, S.L.U.

Todos los derechos reservados.

Introduction

Sjögren's syndrome (SS) is a systematic autoimmune disease characterized by a lymphoid infiltrate in the exocrine glands, that affects mainly in tear and salivary glands causing a decrease in the secretion, which are known as xerophthalmia and xerostomia.¹ This disease can be classified as primary or secondary syndrome (Polyautoimmunity), the first one being an isolated pathology and the later when it is associated to other diseases such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory myopathy and systemic.²

The etiology of Sjögren's syndrome is complex, it is characterized by a lymphocytic infiltration of the exocrine glands and an exaggerated reaction of the activated T and B lymphocytes. The epithelial cells suffer apoptosis induced by signals from T cells. Infiltrated lymphocytes not only induce apoptosis on epithelial cells, they also increase production of proinflammatory cytokines to extend the autoimmune injury.³

Diagnosis of Sjögren's syndrome used to be realized according to six criteria proposed in 2002, known as the AECG-criteria (American-European Consensus Group), which were: oral and eye symptoms related to dry mucous membranes, eye signs to objectively evaluate the integrity of the ocular conjunctive, the histopathology defined by the presence of inflammatory cell infiltration, involvement of salivary glands determined by secretion of saliva, sialography or scintigraphy and the presence of antibodies anti-Ro or anti-La.⁴ ACR criteria to define the SS when the weights from the 5 criteria items below are summed: Labial salivary gland with focal lymphocytic, anti-SSA/Ro positive, ocular Staining Score ≥ 5 , Schirmer's test ≤ 5 mm/5 min in at least 1 eyes and unstimulated whole saliva flow.⁵

Diagnosis of this disease is complex due to the lack of a differential test, also an invasive procedure is needed in order to construct a diagnostic approach, making diagnostic process fearsome for patients. Because of this, with the advances in genomics and proteomics, the aim is to find specific biomarkers for the diagnosis to be sensitive enough to predict the disease's development.⁵

Currently, genomic and proteomic studies exist, which have identified proteins expressed in patients with SS. Kuo et al. carried out a case-control study in which they found a major concentration of MMP-9 and LTF (Lactotransferrin, associated with eye inflammation), but also a decrease of Lidocaine 1 and Lactrine, the later related to the increase of both MMP-9 (matrix metalloproteinase 9) and LTF.⁶




Fig. 1 – Diagram of groups of proteins differentially expressed in Sjögren patients that were identified in previous studies. Proteins were classified by body fluid into saliva, serum, tear and saliva from control groups.

Extracellular proteins from tear and saliva vesicles of SS patients were analyzed, and an overexpression of proteins associated with lymphocyte mediated immunity, neutrophil signaling, calcium receptors and in particular the highlight expression of lipocaline-associated neutrophil gelatinase.⁷

Various studies demonstrate that patients with dry eye and SS have an altered proteomic profile that involve processes such as immunity, inflammation and oxidative stress.⁸ This studies also show that those alterations can be identified in different fluids like saliva, serum, tear and CSF (cerebrospinal liquid).^{9–11}

There is currently an approach to integrate reported protein data to explore biological events in a holistic way.¹² In a tentative approach to this methodology, this study aims to compare reported proteins expressed in controls and patients the with SS in tear, saliva and serum from proteins identified in papers published between 2000 and 2020, to obtain a systematic analyze of proteins expressed in SS patients with the purpose to find proteins that can be used as biomarkers in SS (Fig. 1).

Table 1

Number of proteins	Type of body fluid
396	Saliva
241	Tear
121	Serum
2210	Control group saliva
Number of proteins that were analyzed by body fluid.	

Material and methods

Search for data sets of identified proteins in tears, saliva and serum of Sjögren patients was done using PubMed's database (www.nlm.nih.gov/bsd/pubmed.html). Key words used were Sjögren and/or saliva, serum and tear. Studies from 2000 to 2020 were selected, excluding studies that reported animal or bacterial data; we also selected studies with a LC-MS (Liquid chromatography–mass-spectrometry) analysis.

Data analysis

Differentially expressed proteins from Sjögren patients identified in the studies were classified by body fluid (saliva, serum, tear and saliva from healthy patients) (Table 1). The same process was done for proteins referenced in each article.

Before any analysis was done, a database was created in which every list of proteins, of every article was identified. The database included protein ID, protein name, fluid type and the group that it belonged to (patient or control). Redundant IDs or unidentified sequences were eliminated.

Protein pairing

Protein pairing was carried out in RStudio, using the data frame previously created, in order to identify proteins expressed between Sjögren patients, and proteins expressed in control groups that were also expressed in Sjögren patients.

Data and protein class visualization

PANTHER (Protein ANalysis THrough Evolutionary Relationships <http://www.pantherdb.org/>) and REACTOME 7.0. (<https://reactome.org/PathwayBrowser/#TOOL=AT>) were used in order to explore the type of proteins associated with SS and predominantly enriched metabolic pathways, as a result it is obtained an overrepresentation analysis: a statistical (hypergeometric distribution) test that determines whether certain pathways are over-represented (enriched) in the submitted data.

Results

Ten articles met the selection criteria (excluding studies that reported animal or bacterial data),^{6–17} in total 2968 proteins were analyzed (Table 1). In control group were found 2210 saliva proteins and SS group were found 758 proteins, which were classified into 3 groups saliva (396 proteins), tear (241 proteins) and serum (121 proteins).

Table 2

Protein ID	Protein name
P01008	Antithrombin-III
P12830	Cadherin-1
P17174	Aspartate aminotransferase
P01024	Complement C3
P02765	Alpha-2-HS-glycoprotein
List of shared proteins in ss-saliva, ss-serum, and ss-tear.	

Table 3

Intersection	Enriched pathways	p-Value
Saliva/tear/serum	Extracellular serine/threonine protein kinase FAM20C	8.75E–5
Saliva/tear/serum	Regulation of insulin-like growth factor (IGF) transport and uptake by insulin-like growth factor binding proteins (IGFBPs)	3.97E–4
Saliva/tear/serum	Neutrophil degranulation	7.45E–3
Enriched pathways. The proteins were mapped using REACTOME 7.0.		

An initial pairing using RStudio was done, in which 5 proteins were found in all Sjögren patients and were not in control groups (Table 2). Next, all proteins from SS patients were mapped using REACTOME 7.0, Table 3 shows enriched pathways.

Discussion and conclusions

Clinical diagnosis and follow-up of dry eye patients is a great challenge to health professionals because there seems to be no clear correlation between symptoms and results of clinical tests,⁵ which highlights the necessity of new diagnosis methods.^{7–17} This study aims to find proteins that can be used as biomarkers in SS, using an adaptation to Ghosvavand et al. protocol, that tends to generally integrate reported data to explore events in a holistic way.¹²

Among the proteins that were found two caught our attention: antithrombin III and E-cadherin, since the increase of its expression is related to SS. Antithrombin III is a glycoprotein dependent on liver synthesized vitamin k, which acts as natural inhibitor of coagulation.¹⁸ Antithrombin III inhibits multiple points of the Coagulation cascade, and because of this, its deficiency is associated with thrombosis.¹⁸ Of all acquired thrombophilias, antiphospholipid syndrome is the most frequent with 28% of the cases, and it has been associated with other pathologies like Sjögren, rheumatoid arthritis, vasculitis and Crohn's disease.^{18,19}

E-cadherin is an adhesion molecule normally expressed on epithelial cells, required for the formation of adherence junctions between mature epithelial cells, regulating differentiation, proliferation and apoptosis high levels of E-cadherin in serum have been associated with Sjögren and skin inflammation.²⁰ To our surprise high levels of E-cadherin were

also reported in saliva and tears of SS patients which makes us suggest the use of this protein as a potential biomarker.

Of the enriched pathways, neutrophil degranulation pathway has been related in many occasions with SS,²¹ which make us think that it could be related with E-cadherin expression that affects polarization in immune cells, thus driving cell signaling out of control.²²

The other two pathways are indirectly associated with autoimmune diseases. Extracellular serine/threonine protein kinase FAM20C that phosphorylates secretory pathway and plays a key role in biomineralization of bones and teeth. In mouse was demonstrate that the Emk protein kinase is essential for maintaining immune system homeostasis and that loss of Emk may contribute to autoimmune disease in mammals.²³

The IGF/IGF pathway plays important and diverse roles in tissue development and function. It regulates cell cycle progression, apoptosis, and the translation of proteins. This signaling may also participate in the pathogenesis of autoimmune diseases, although its relationship with these processes seems complex and relatively unexplored, but suggests that this pathway might constitute an attractive therapeutic target.²⁴

Finally, this study suggests antithrombin III and E-cadherin. as biomarkers in SS, because these proteins are differentially expressed in plasma, blood and tear, and suggests neutrophil degranulation pathway as a target for SS.

Conflict of interest

The authors declare that they have no conflict of interest.

REFERENCES

1. Fernández Castro M. Síndrome de Sjögren. *Medicine*. 2013;11:1865–73, [http://dx.doi.org/10.1016/S0304-5412\(13\)70540-7](http://dx.doi.org/10.1016/S0304-5412(13)70540-7).
2. Alani H, Henty JR, Thompson NL, Jury E, Ciurtin C. Systematic review and meta-analysis of the epidemiology of polyautoimmunity in Sjögren's syndrome (secondary Sjögren's syndrome) focusing on autoimmune rheumatic diseases. *Scand J Rheumatol*. 2018;47:141–54, <http://dx.doi.org/10.1080/03009742.2017.1324909>.
3. Ramos Herrera IM, Martínez Ceccopieri DA, Chávez AH, Centeno Flores MW, Valls RV, Reumatología. *CAM Curso de actualización médica*. Nueva York, NY: McGraw-Hill Education; 2016. p. 407–20.
4. Uribe Olivares R, Fregoso Fregoso M, Monroy Rodríguez JA. *Fisiopatología. La ciencia del porqué y el cómo*. Marrickville: Elsevier; 2018.
5. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al., International Sjögren's Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: a consensus and data-driven methodology involving three international patient cohorts. *Arthritis Rheumatol*. 2017;69:35–45, <http://dx.doi.org/10.1002/art.39859>.
6. Kuo MT, Fang PC, Chao TL, Chen A, Lai YH, Huang YT, et al. Tear proteomics approach to monitoring Sjögren syndrome or dry eye disease. *Int J Mol Sci*. 2019;20:1932, <http://dx.doi.org/10.3390/ijms20081932>.
7. Aqrabi LA, Galtung HK, Vestad B, Øvstebø R, Thiede B, Rusthen S, et al. Identification of potential saliva and tear biomarkers in primary Sjögren's syndrome, utilising the extraction of extracellular vesicles and proteomics analysis. *Arthritis Res Ther*. 2017;19:14, <http://dx.doi.org/10.1186/s13075-017-1228-x>.
8. Li B, Sheng M, Li J, Yan G, Lin A, Li M, et al. Tear proteomic analysis of Sjögren syndrome patients with dry eye syndrome by two-dimensional-nano-liquid chromatography coupled with tandem mass spectrometry. *Sci Rep*. 2014;4:5772, <http://dx.doi.org/10.1038/srep05772>.
9. Cecchetti A, Finamore F, Ucciferri N, Donati V, Mattii L, Polizzi E, et al. Phenotyping multiple subsets in Sjögren's syndrome: a salivary proteomic SWATH-MS approach towards precision medicine. *Clin Proteomics*. 2019;16:26, <http://dx.doi.org/10.1186/s12014-019-9245-1>.
10. Delaleu N, Mydel P, Kwee I, Brun JG, Jonsson MV, Jonsson R. High fidelity between saliva proteomics and the biologic state of salivary glands defines biomarker signatures for primary Sjögren's syndrome. *Arthritis Rheumatol*. 2015;67:1084–95, <http://dx.doi.org/10.1002/art.39015>.
11. Larssen E, Brede C, Hjelle A, Tjensvoll AB, Norheim KB, Bårdsen K, et al. Fatigue in primary Sjögren's syndrome: a proteomic pilot study of cerebrospinal fluid. *SAGE Open Med*. 2019;7, <http://dx.doi.org/10.1177/2050312119850390>, 2050312119850390.
12. Ghojvand S, Bagheri F, Mesrian Tanha H. Integrative meta-analysis of publically available microarray datasets of several epithelial cell lines identifies biological processes affected by silver nanoparticles exposure. *Comp Biochem Physiol C Toxicol Pharmacol*. 2019;216:67–74, <http://dx.doi.org/10.1016/j.cbpc.2018.11.003>.
13. Delaleu N, Mydel P, Brun JG, Jonsson MV, Alimonti A, Jonsson R. Sjögren's syndrome patients with ectopic germinal centers present with a distinct salivary proteome. *Rheumatology (Oxford)*. 2016;55:1127–37, <http://dx.doi.org/10.1093/rheumatology/kew013>.
14. Deutsch O, Krief G, Kontinen YT, Zaks B, Wong DT, Aframian DJ, et al. Identification of Sjögren's syndrome oral fluid biomarker candidates following high-abundance protein depletion. *Rheumatology (Oxford)*. 2015;54:884–90, <http://dx.doi.org/10.1093/rheumatology/keu405>.
15. Bodewes ILA, van der Spek PJ, Leon LG, Wijkhuijs AJM, van Helden-Meeuwse CG, Tas L, et al. Fatigue in Sjögren's syndrome: a search for biomarkers and treatment targets. *Front Immunol*. 2019;10:312, <http://dx.doi.org/10.3389/fimmu.2019.00312>.
16. Vitorino R, Barros A, Caseiro A, Domingues P, Duarte J, Amado F. Towards defining the whole salivary peptidome. *Proteomics Clin Appl*. 2009;3:528–40, <http://dx.doi.org/10.1002/prca.200800183>.
17. Peluso G, De Santis M, Inzitari R, Fanali C, Cabras T, Messana I, et al. Proteomic study of salivary peptides and proteins in patients with Sjögren's syndrome before and after pilocarpine treatment. *Arthritis Rheum*. 2007;56:2216–22, <http://dx.doi.org/10.1002/art.22738>.
18. Hanly JG. Antiphospholipid syndrome: an overview. *CMAJ*. 2003;168:1675–82.
19. Koh MS, Goh KY, Chen C, Howe HS. Cerebral infarct mimicking glioma in Sjögren's syndrome. *Hong Kong Med J*. 2002;8:292–4.
20. Jonsson MV, Salomonsson S, Øijordsbakken G, Skarstein K. Elevated serum levels of soluble E-cadherin in patients with primary Sjögren's syndrome. *Scand J Immunol*. 2005;62:552–9, <http://dx.doi.org/10.1111/j.1365-3083.2005.01698.x>.
21. Aqrabi LA, Chen X, Jensen JL, Morthen MK, Thiede B, Utthim ØA, et al. Severity of clinical dry eye manifestations

- influences protein expression in tear fluid of patients with primary Sjögren's syndrome. PLOS ONE. 2018;13, <http://dx.doi.org/10.1371/journal.pone.0205762>, e0205762.
22. Le Floch A, Jalil A, Franciszkiewicz K, Validire P, Vergnon I, Mami-Chouaib F. Minimal engagement of CD103 on cytotoxic T lymphocytes with an E-cadherin-Fc molecule triggers lytic granule polarization via a phospholipase Cgamma-dependent pathway. Cancer Res. 2011;71:328–38, <http://dx.doi.org/10.1158/0008-5472.CAN-10-2457>.
23. Hurov JB, Stappenbeck TS, Zmasek CM, White LS, Ranganath SH, Russell JH, et al. Immune system dysfunction and autoimmune disease in mice lacking Emk (Par-1) protein kinase. Mol Cell Biol. 2001;21:3206–19, <http://dx.doi.org/10.1128/MCB.21.9.3206-3219.2001>.
24. Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev. 2010;62:199–236, <http://dx.doi.org/10.1124/pr.109.002469>.